Royalty Pharma (RPRX) Liabilities and Shareholders Equity (2019 - 2026)

Royalty Pharma has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $19.8 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $19.8 billion, up 12.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $77.1 billion (up 7.8% YoY), and the FY2025 annual result was $19.6 billion, up 7.67% from the prior year.
• Liabilities and Shareholders Equity came in at $19.8 billion for Q1 2026 at Royalty Pharma, up from $19.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $19.8 billion in Q1 2026 to a low of $15.9 billion in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $17.7 billion (2024), against an average of $17.7 billion.
• Across the five-year window, Liabilities and Shareholders Equity declined 10.28% in 2023 and climbed 13.79% in 2024, its largest moves.
• Royalty Pharma's Liabilities and Shareholders Equity stood at $16.8 billion in 2022, then slipped by 2.57% to $16.4 billion in 2023, then rose by 11.24% to $18.2 billion in 2024, then climbed by 7.67% to $19.6 billion in 2025, then gained by 0.99% to $19.8 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $19.8 billion (Q1 2026), $19.6 billion (Q4 2025), and $19.3 billion (Q3 2025), per Business Quant data.